VC fund dedicated to psychedelic meds launches in UK

In the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – magic or otherwise – and venture capital money is starting to follow.

Purdue to pay $8.3bn after admitting criminal charges in opi...

After years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in the US opioid epidemic that will cost it up to $8.3 billion.

After final $600M opioid settlement, Indivior looks to the f...

UK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in the US behind it, after agreeing a $600 million settlement.

Orexo eyes launch of digital therapy for heavy drinkers this...

Addiction firm Orexo licenses app for alcohol use disorder

England is risking its own opioid epidemic, says PHE